Web Date: December 6, 2017
Obsidian launches with $49.5 million to fine tune cellular and gene therapies
Armed with $49.5 million in its first formal round of funding, Obsidian Therapeutics has launched to fine tune the activity of cellular and gene therapies. Led by serial entrepreneur Michael Gilman, the Boston-based biotech firm aims to make the treatments safer and more effective across a broader range of diseases.
Ever since early clinical trials suggested chimeric antigen receptor (CAR) T cells could quickly obliterate blood cancer in some . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society